Skip to Content


by Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)
Vox
July 20, 2018

Read the full article

From the article:

Right now, in the above circumstances and when there isn’t an actual drug shortage, “we don’t have a good policy solution,” Scott Gottlieb, the FDA commissioner, told me Thursday in a brief phone interview.

The policy would be applied in limited circumstances — only for generic drugs and only temporarily, it appears — and could therefore have only a limited effect, but experts still say it’s a good idea.

“I think this is a smart move for the administration,” Rachel Sachs, a law professor at Washington University in St. Louis, who has generally been unimpressed by what the Trump administration has proposed on drug prices, told me.

Read more here!

Read the full article

Tags

fda   health care finance   health care reform   health law policy   pharmaceuticals   rachel sachs